nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—ABCB1—esophageal cancer	0.787	1	CbGaD
Dihydroergotamine—Vasospasm—Capecitabine—esophageal cancer	0.00432	0.0328	CcSEcCtD
Dihydroergotamine—Pain—Carboplatin—esophageal cancer	0.00208	0.0158	CcSEcCtD
Dihydroergotamine—Hiccups—Cisplatin—esophageal cancer	0.002	0.0152	CcSEcCtD
Dihydroergotamine—Ventricular fibrillation—Capecitabine—esophageal cancer	0.00193	0.0146	CcSEcCtD
Dihydroergotamine—Body temperature increased—Carboplatin—esophageal cancer	0.00192	0.0146	CcSEcCtD
Dihydroergotamine—Tingling sensation—Capecitabine—esophageal cancer	0.00183	0.014	CcSEcCtD
Dihydroergotamine—Myocardial ischaemia—Capecitabine—esophageal cancer	0.00183	0.014	CcSEcCtD
Dihydroergotamine—Rigors—Capecitabine—esophageal cancer	0.00181	0.0137	CcSEcCtD
Dihydroergotamine—Petechiae—Capecitabine—esophageal cancer	0.00179	0.0136	CcSEcCtD
Dihydroergotamine—Musculoskeletal stiffness—Capecitabine—esophageal cancer	0.00164	0.0125	CcSEcCtD
Dihydroergotamine—Herpes simplex—Capecitabine—esophageal cancer	0.0016	0.0122	CcSEcCtD
Dihydroergotamine—Gait disturbance—Capecitabine—esophageal cancer	0.00151	0.0115	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00148	0.0113	CcSEcCtD
Dihydroergotamine—Hiccups—Capecitabine—esophageal cancer	0.00147	0.0112	CcSEcCtD
Dihydroergotamine—Stupor—Methotrexate—esophageal cancer	0.00147	0.0112	CcSEcCtD
Dihydroergotamine—Influenza like illness—Capecitabine—esophageal cancer	0.00143	0.0109	CcSEcCtD
Dihydroergotamine—Depressed level of consciousness—Capecitabine—esophageal cancer	0.00142	0.0108	CcSEcCtD
Dihydroergotamine—Face oedema—Cisplatin—esophageal cancer	0.0014	0.0107	CcSEcCtD
Dihydroergotamine—Petechiae—Methotrexate—esophageal cancer	0.00133	0.0101	CcSEcCtD
Dihydroergotamine—Cramp muscle—Cisplatin—esophageal cancer	0.00131	0.00995	CcSEcCtD
Dihydroergotamine—Abnormal vision—Capecitabine—esophageal cancer	0.00129	0.00978	CcSEcCtD
Dihydroergotamine—Mental disability—Capecitabine—esophageal cancer	0.00128	0.00973	CcSEcCtD
Dihydroergotamine—Speech disorder—Methotrexate—esophageal cancer	0.00128	0.00971	CcSEcCtD
Dihydroergotamine—Ear pain—Capecitabine—esophageal cancer	0.00125	0.00954	CcSEcCtD
Dihydroergotamine—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.00122	0.00931	CcSEcCtD
Dihydroergotamine—Sweating increased—Cisplatin—esophageal cancer	0.00122	0.0093	CcSEcCtD
Dihydroergotamine—Swelling—Capecitabine—esophageal cancer	0.00121	0.00923	CcSEcCtD
Dihydroergotamine—Herpes simplex—Methotrexate—esophageal cancer	0.00119	0.00906	CcSEcCtD
Dihydroergotamine—Eye pain—Capecitabine—esophageal cancer	0.00119	0.00902	CcSEcCtD
Dihydroergotamine—Hot flush—Capecitabine—esophageal cancer	0.00114	0.0087	CcSEcCtD
Dihydroergotamine—Menopausal symptoms—Capecitabine—esophageal cancer	0.00113	0.00863	CcSEcCtD
Dihydroergotamine—Acute coronary syndrome—Cisplatin—esophageal cancer	0.0011	0.00839	CcSEcCtD
Dihydroergotamine—Vaginal inflammation—Methotrexate—esophageal cancer	0.0011	0.00835	CcSEcCtD
Dihydroergotamine—Myocardial infarction—Cisplatin—esophageal cancer	0.0011	0.00834	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00109	0.00831	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Cisplatin—esophageal cancer	0.00109	0.00827	CcSEcCtD
Dihydroergotamine—Cystitis noninfective—Methotrexate—esophageal cancer	0.00107	0.00816	CcSEcCtD
Dihydroergotamine—Cystitis—Methotrexate—esophageal cancer	0.00106	0.00806	CcSEcCtD
Dihydroergotamine—Depressed level of consciousness—Methotrexate—esophageal cancer	0.00106	0.00806	CcSEcCtD
Dihydroergotamine—Migraine—Capecitabine—esophageal cancer	0.00105	0.00801	CcSEcCtD
Dihydroergotamine—Vaginal infection—Methotrexate—esophageal cancer	0.00104	0.00788	CcSEcCtD
Dihydroergotamine—Face oedema—Capecitabine—esophageal cancer	0.00103	0.00786	CcSEcCtD
Dihydroergotamine—Bladder pain—Methotrexate—esophageal cancer	0.000992	0.00755	CcSEcCtD
Dihydroergotamine—Visual impairment—Cisplatin—esophageal cancer	0.000968	0.00736	CcSEcCtD
Dihydroergotamine—Muscular weakness—Capecitabine—esophageal cancer	0.000944	0.00718	CcSEcCtD
Dihydroergotamine—Tinnitus—Cisplatin—esophageal cancer	0.000936	0.00712	CcSEcCtD
Dihydroergotamine—Flushing—Cisplatin—esophageal cancer	0.000932	0.00709	CcSEcCtD
Dihydroergotamine—Dysphagia—Capecitabine—esophageal cancer	0.000925	0.00704	CcSEcCtD
Dihydroergotamine—Bronchospasm—Capecitabine—esophageal cancer	0.00091	0.00692	CcSEcCtD
Dihydroergotamine—Sweating increased—Capecitabine—esophageal cancer	0.000901	0.00686	CcSEcCtD
Dihydroergotamine—Angina pectoris—Capecitabine—esophageal cancer	0.000901	0.00686	CcSEcCtD
Dihydroergotamine—Bronchitis—Capecitabine—esophageal cancer	0.00089	0.00677	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00086	0.00654	CcSEcCtD
Dihydroergotamine—Muscle spasms—Cisplatin—esophageal cancer	0.000841	0.0064	CcSEcCtD
Dihydroergotamine—Tremor—Cisplatin—esophageal cancer	0.000819	0.00623	CcSEcCtD
Dihydroergotamine—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000813	0.00619	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000813	0.00619	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Cisplatin—esophageal cancer	0.000811	0.00617	CcSEcCtD
Dihydroergotamine—Myocardial infarction—Capecitabine—esophageal cancer	0.000808	0.00615	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Capecitabine—esophageal cancer	0.000802	0.0061	CcSEcCtD
Dihydroergotamine—Malaise—Cisplatin—esophageal cancer	0.000788	0.006	CcSEcCtD
Dihydroergotamine—Epistaxis—Capecitabine—esophageal cancer	0.000778	0.00592	CcSEcCtD
Dihydroergotamine—Myalgia—Cisplatin—esophageal cancer	0.000744	0.00566	CcSEcCtD
Dihydroergotamine—Rhinitis—Capecitabine—esophageal cancer	0.000742	0.00565	CcSEcCtD
Dihydroergotamine—Anxiety—Cisplatin—esophageal cancer	0.000742	0.00564	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Capecitabine—esophageal cancer	0.000737	0.0056	CcSEcCtD
Dihydroergotamine—Discomfort—Cisplatin—esophageal cancer	0.000735	0.0056	CcSEcCtD
Dihydroergotamine—Pharyngitis—Capecitabine—esophageal cancer	0.000735	0.00559	CcSEcCtD
Dihydroergotamine—Oedema—Cisplatin—esophageal cancer	0.000714	0.00543	CcSEcCtD
Dihydroergotamine—Visual impairment—Capecitabine—esophageal cancer	0.000714	0.00543	CcSEcCtD
Dihydroergotamine—Tachycardia—Cisplatin—esophageal cancer	0.000696	0.0053	CcSEcCtD
Dihydroergotamine—Tinnitus—Capecitabine—esophageal cancer	0.00069	0.00525	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Cisplatin—esophageal cancer	0.00069	0.00525	CcSEcCtD
Dihydroergotamine—Flushing—Capecitabine—esophageal cancer	0.000687	0.00523	CcSEcCtD
Dihydroergotamine—Anorexia—Cisplatin—esophageal cancer	0.00068	0.00517	CcSEcCtD
Dihydroergotamine—Hypotension—Cisplatin—esophageal cancer	0.000667	0.00507	CcSEcCtD
Dihydroergotamine—Chills—Capecitabine—esophageal cancer	0.000664	0.00505	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00065	0.00495	CcSEcCtD
Dihydroergotamine—Paraesthesia—Cisplatin—esophageal cancer	0.000641	0.00487	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00064	0.00487	CcSEcCtD
Dihydroergotamine—Dyspnoea—Cisplatin—esophageal cancer	0.000636	0.00484	CcSEcCtD
Dihydroergotamine—Decreased appetite—Cisplatin—esophageal cancer	0.00062	0.00472	CcSEcCtD
Dihydroergotamine—Muscle spasms—Capecitabine—esophageal cancer	0.00062	0.00471	CcSEcCtD
Dihydroergotamine—Pain—Cisplatin—esophageal cancer	0.00061	0.00464	CcSEcCtD
Dihydroergotamine—Tremor—Capecitabine—esophageal cancer	0.000604	0.00459	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Capecitabine—esophageal cancer	0.000598	0.00455	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Methotrexate—esophageal cancer	0.000597	0.00454	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Cisplatin—esophageal cancer	0.000588	0.00447	CcSEcCtD
Dihydroergotamine—Malaise—Capecitabine—esophageal cancer	0.000581	0.00442	CcSEcCtD
Dihydroergotamine—Epistaxis—Methotrexate—esophageal cancer	0.000579	0.00441	CcSEcCtD
Dihydroergotamine—Vertigo—Capecitabine—esophageal cancer	0.000579	0.00441	CcSEcCtD
Dihydroergotamine—Palpitations—Capecitabine—esophageal cancer	0.00057	0.00433	CcSEcCtD
Dihydroergotamine—Body temperature increased—Cisplatin—esophageal cancer	0.000564	0.00429	CcSEcCtD
Dihydroergotamine—Hypertension—Capecitabine—esophageal cancer	0.000556	0.00423	CcSEcCtD
Dihydroergotamine—Arthralgia—Capecitabine—esophageal cancer	0.000549	0.00417	CcSEcCtD
Dihydroergotamine—Myalgia—Capecitabine—esophageal cancer	0.000549	0.00417	CcSEcCtD
Dihydroergotamine—Pharyngitis—Methotrexate—esophageal cancer	0.000547	0.00416	CcSEcCtD
Dihydroergotamine—Anxiety—Capecitabine—esophageal cancer	0.000547	0.00416	CcSEcCtD
Dihydroergotamine—Discomfort—Capecitabine—esophageal cancer	0.000542	0.00412	CcSEcCtD
Dihydroergotamine—Dry mouth—Capecitabine—esophageal cancer	0.000537	0.00408	CcSEcCtD
Dihydroergotamine—Visual impairment—Methotrexate—esophageal cancer	0.000531	0.00404	CcSEcCtD
Dihydroergotamine—Confusional state—Capecitabine—esophageal cancer	0.00053	0.00404	CcSEcCtD
Dihydroergotamine—Oedema—Capecitabine—esophageal cancer	0.000526	0.004	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Cisplatin—esophageal cancer	0.000526	0.004	CcSEcCtD
Dihydroergotamine—Shock—Capecitabine—esophageal cancer	0.000518	0.00394	CcSEcCtD
Dihydroergotamine—Tinnitus—Methotrexate—esophageal cancer	0.000514	0.00391	CcSEcCtD
Dihydroergotamine—Tachycardia—Capecitabine—esophageal cancer	0.000513	0.00391	CcSEcCtD
Dihydroergotamine—Asthenia—Cisplatin—esophageal cancer	0.000512	0.0039	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Capecitabine—esophageal cancer	0.000509	0.00387	CcSEcCtD
Dihydroergotamine—Anorexia—Capecitabine—esophageal cancer	0.000501	0.00381	CcSEcCtD
Dihydroergotamine—Chills—Methotrexate—esophageal cancer	0.000495	0.00376	CcSEcCtD
Dihydroergotamine—Hypotension—Capecitabine—esophageal cancer	0.000492	0.00374	CcSEcCtD
Dihydroergotamine—Diarrhoea—Cisplatin—esophageal cancer	0.000488	0.00371	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000479	0.00365	CcSEcCtD
Dihydroergotamine—Insomnia—Capecitabine—esophageal cancer	0.000476	0.00362	CcSEcCtD
Dihydroergotamine—Paraesthesia—Capecitabine—esophageal cancer	0.000472	0.00359	CcSEcCtD
Dihydroergotamine—Dyspnoea—Capecitabine—esophageal cancer	0.000469	0.00357	CcSEcCtD
Dihydroergotamine—Dyspepsia—Capecitabine—esophageal cancer	0.000463	0.00352	CcSEcCtD
Dihydroergotamine—Decreased appetite—Capecitabine—esophageal cancer	0.000457	0.00348	CcSEcCtD
Dihydroergotamine—Vomiting—Cisplatin—esophageal cancer	0.000454	0.00345	CcSEcCtD
Dihydroergotamine—Fatigue—Capecitabine—esophageal cancer	0.000454	0.00345	CcSEcCtD
Dihydroergotamine—Rash—Cisplatin—esophageal cancer	0.00045	0.00342	CcSEcCtD
Dihydroergotamine—Pain—Capecitabine—esophageal cancer	0.00045	0.00342	CcSEcCtD
Dihydroergotamine—Dermatitis—Cisplatin—esophageal cancer	0.00045	0.00342	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Methotrexate—esophageal cancer	0.000445	0.00339	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Capecitabine—esophageal cancer	0.000433	0.0033	CcSEcCtD
Dihydroergotamine—Malaise—Methotrexate—esophageal cancer	0.000433	0.00329	CcSEcCtD
Dihydroergotamine—Vertigo—Methotrexate—esophageal cancer	0.000431	0.00328	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00043	0.00327	CcSEcCtD
Dihydroergotamine—Nausea—Cisplatin—esophageal cancer	0.000424	0.00322	CcSEcCtD
Dihydroergotamine—Urticaria—Capecitabine—esophageal cancer	0.000418	0.00318	CcSEcCtD
Dihydroergotamine—Abdominal pain—Capecitabine—esophageal cancer	0.000416	0.00316	CcSEcCtD
Dihydroergotamine—Body temperature increased—Capecitabine—esophageal cancer	0.000416	0.00316	CcSEcCtD
Dihydroergotamine—Arthralgia—Methotrexate—esophageal cancer	0.000408	0.00311	CcSEcCtD
Dihydroergotamine—Myalgia—Methotrexate—esophageal cancer	0.000408	0.00311	CcSEcCtD
Dihydroergotamine—Discomfort—Methotrexate—esophageal cancer	0.000404	0.00307	CcSEcCtD
Dihydroergotamine—Confusional state—Methotrexate—esophageal cancer	0.000395	0.003	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Capecitabine—esophageal cancer	0.000388	0.00295	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Methotrexate—esophageal cancer	0.000379	0.00288	CcSEcCtD
Dihydroergotamine—Asthenia—Capecitabine—esophageal cancer	0.000377	0.00287	CcSEcCtD
Dihydroergotamine—Anorexia—Methotrexate—esophageal cancer	0.000373	0.00284	CcSEcCtD
Dihydroergotamine—Pruritus—Capecitabine—esophageal cancer	0.000372	0.00283	CcSEcCtD
Dihydroergotamine—Hypotension—Methotrexate—esophageal cancer	0.000366	0.00278	CcSEcCtD
Dihydroergotamine—Diarrhoea—Capecitabine—esophageal cancer	0.00036	0.00274	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000357	0.00271	CcSEcCtD
Dihydroergotamine—Insomnia—Methotrexate—esophageal cancer	0.000354	0.00269	CcSEcCtD
Dihydroergotamine—Paraesthesia—Methotrexate—esophageal cancer	0.000352	0.00268	CcSEcCtD
Dihydroergotamine—Dyspnoea—Methotrexate—esophageal cancer	0.000349	0.00266	CcSEcCtD
Dihydroergotamine—Somnolence—Methotrexate—esophageal cancer	0.000348	0.00265	CcSEcCtD
Dihydroergotamine—Dizziness—Capecitabine—esophageal cancer	0.000348	0.00265	CcSEcCtD
Dihydroergotamine—Dyspepsia—Methotrexate—esophageal cancer	0.000345	0.00262	CcSEcCtD
Dihydroergotamine—Decreased appetite—Methotrexate—esophageal cancer	0.00034	0.00259	CcSEcCtD
Dihydroergotamine—Fatigue—Methotrexate—esophageal cancer	0.000338	0.00257	CcSEcCtD
Dihydroergotamine—Pain—Methotrexate—esophageal cancer	0.000335	0.00255	CcSEcCtD
Dihydroergotamine—Vomiting—Capecitabine—esophageal cancer	0.000334	0.00254	CcSEcCtD
Dihydroergotamine—Rash—Capecitabine—esophageal cancer	0.000332	0.00252	CcSEcCtD
Dihydroergotamine—Dermatitis—Capecitabine—esophageal cancer	0.000331	0.00252	CcSEcCtD
Dihydroergotamine—Headache—Capecitabine—esophageal cancer	0.00033	0.00251	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Methotrexate—esophageal cancer	0.000323	0.00245	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00032	0.00244	CcSEcCtD
Dihydroergotamine—Nausea—Capecitabine—esophageal cancer	0.000312	0.00238	CcSEcCtD
Dihydroergotamine—Urticaria—Methotrexate—esophageal cancer	0.000311	0.00237	CcSEcCtD
Dihydroergotamine—Body temperature increased—Methotrexate—esophageal cancer	0.00031	0.00236	CcSEcCtD
Dihydroergotamine—Abdominal pain—Methotrexate—esophageal cancer	0.00031	0.00236	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Methotrexate—esophageal cancer	0.000289	0.00219	CcSEcCtD
Dihydroergotamine—Asthenia—Methotrexate—esophageal cancer	0.000281	0.00214	CcSEcCtD
Dihydroergotamine—Pruritus—Methotrexate—esophageal cancer	0.000277	0.00211	CcSEcCtD
Dihydroergotamine—Diarrhoea—Methotrexate—esophageal cancer	0.000268	0.00204	CcSEcCtD
Dihydroergotamine—Dizziness—Methotrexate—esophageal cancer	0.000259	0.00197	CcSEcCtD
Dihydroergotamine—Vomiting—Methotrexate—esophageal cancer	0.000249	0.00189	CcSEcCtD
Dihydroergotamine—Rash—Methotrexate—esophageal cancer	0.000247	0.00188	CcSEcCtD
Dihydroergotamine—Dermatitis—Methotrexate—esophageal cancer	0.000247	0.00188	CcSEcCtD
Dihydroergotamine—Headache—Methotrexate—esophageal cancer	0.000245	0.00187	CcSEcCtD
Dihydroergotamine—Nausea—Methotrexate—esophageal cancer	0.000233	0.00177	CcSEcCtD
Dihydroergotamine—Ergotamine—ABCB1—esophageal cancer	0.000171	0.509	CrCbGaD
Dihydroergotamine—Bromocriptine—ABCB1—esophageal cancer	0.000165	0.491	CrCbGaD
Dihydroergotamine—ADRA2A—Metabolism—ALDOB—esophageal cancer	4.59e-05	0.000567	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—GHRL—esophageal cancer	4.58e-05	0.000565	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—FBXW7—esophageal cancer	4.57e-05	0.000564	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PFN1—esophageal cancer	4.56e-05	0.000563	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—FBXW7—esophageal cancer	4.54e-05	0.00056	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—GHRL—esophageal cancer	4.52e-05	0.000558	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NOTCH3—esophageal cancer	4.52e-05	0.000558	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PSME2—esophageal cancer	4.5e-05	0.000555	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PSME1—esophageal cancer	4.5e-05	0.000555	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	4.48e-05	0.000553	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ANXA1—esophageal cancer	4.48e-05	0.000552	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—NOS2—esophageal cancer	4.47e-05	0.000552	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—FBXW7—esophageal cancer	4.44e-05	0.000548	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—GNG7—esophageal cancer	4.43e-05	0.000547	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GAPDH—esophageal cancer	4.42e-05	0.000545	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CRABP1—esophageal cancer	4.38e-05	0.000541	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ADH7—esophageal cancer	4.37e-05	0.000539	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PLCE1—esophageal cancer	4.37e-05	0.000539	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SST—esophageal cancer	4.35e-05	0.000537	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	4.33e-05	0.000535	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NOTCH3—esophageal cancer	4.24e-05	0.000524	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—GHRL—esophageal cancer	4.24e-05	0.000524	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—FBXW7—esophageal cancer	4.17e-05	0.000515	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NOTCH2—esophageal cancer	4.17e-05	0.000515	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GNG7—esophageal cancer	4.17e-05	0.000514	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—XIAP—esophageal cancer	4.15e-05	0.000513	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NOTCH2—esophageal cancer	4.14e-05	0.000511	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	4.12e-05	0.000509	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ELMO1—esophageal cancer	4.1e-05	0.000506	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NOTCH2—esophageal cancer	4.05e-05	0.0005	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—CREBBP—esophageal cancer	4.02e-05	0.000496	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKAP13—esophageal cancer	4e-05	0.000494	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CTNNA1—esophageal cancer	3.93e-05	0.000485	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	3.92e-05	0.000484	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CXCL2—esophageal cancer	3.9e-05	0.000482	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ALDH2—esophageal cancer	3.9e-05	0.000482	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ADH1B—esophageal cancer	3.83e-05	0.000473	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NOTCH2—esophageal cancer	3.81e-05	0.00047	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	3.75e-05	0.000462	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—BLVRB—esophageal cancer	3.72e-05	0.00046	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SLC52A3—esophageal cancer	3.72e-05	0.00046	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GSTT1—esophageal cancer	3.71e-05	0.000458	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TGFBR2—esophageal cancer	3.7e-05	0.000457	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HIST1H2BM—esophageal cancer	3.7e-05	0.000456	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TGFBR2—esophageal cancer	3.67e-05	0.000453	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CYP2A6—esophageal cancer	3.67e-05	0.000453	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PDE4D—esophageal cancer	3.66e-05	0.000452	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—TYMP—esophageal cancer	3.66e-05	0.000452	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PSME1—esophageal cancer	3.65e-05	0.00045	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PSME2—esophageal cancer	3.65e-05	0.00045	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ANXA1—esophageal cancer	3.63e-05	0.000448	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—NOS3—esophageal cancer	3.6e-05	0.000444	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TGFBR2—esophageal cancer	3.59e-05	0.000444	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	3.59e-05	0.000443	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP26A1—esophageal cancer	3.56e-05	0.00044	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SST—esophageal cancer	3.53e-05	0.000436	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	3.51e-05	0.000434	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—SMAD4—esophageal cancer	3.5e-05	0.000432	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GNG7—esophageal cancer	3.48e-05	0.00043	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ENO1—esophageal cancer	3.48e-05	0.000429	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTGS1—esophageal cancer	3.48e-05	0.000429	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—SMAD4—esophageal cancer	3.47e-05	0.000429	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ALOX15—esophageal cancer	3.47e-05	0.000428	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NOTCH3—esophageal cancer	3.44e-05	0.000425	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—GHRL—esophageal cancer	3.44e-05	0.000425	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PSME1—esophageal cancer	3.43e-05	0.000423	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PSME2—esophageal cancer	3.43e-05	0.000423	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—SMAD4—esophageal cancer	3.4e-05	0.00042	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—FBXW7—esophageal cancer	3.39e-05	0.000418	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TGFBR2—esophageal cancer	3.38e-05	0.000417	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTO1—esophageal cancer	3.31e-05	0.000409	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—TPI1—esophageal cancer	3.31e-05	0.000409	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—XIAP—esophageal cancer	3.26e-05	0.000403	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SMAD4—esophageal cancer	3.2e-05	0.000394	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ALDOB—esophageal cancer	3.17e-05	0.000392	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SLC10A2—esophageal cancer	3.17e-05	0.000391	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CA1—esophageal cancer	3.17e-05	0.000391	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CTNNA1—esophageal cancer	3.09e-05	0.000381	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NOTCH2—esophageal cancer	3.09e-05	0.000381	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CXCL2—esophageal cancer	3.07e-05	0.000379	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GAPDH—esophageal cancer	3.06e-05	0.000377	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	3.05e-05	0.000376	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CRABP1—esophageal cancer	3.03e-05	0.000374	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CYP1B1—esophageal cancer	2.96e-05	0.000365	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.95e-05	0.000364	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CA2—esophageal cancer	2.9e-05	0.000357	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GNG7—esophageal cancer	2.88e-05	0.000356	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PSME2—esophageal cancer	2.87e-05	0.000354	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PSME1—esophageal cancer	2.87e-05	0.000354	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HIF1A—esophageal cancer	2.86e-05	0.000354	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ANXA1—esophageal cancer	2.85e-05	0.000352	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HIF1A—esophageal cancer	2.84e-05	0.000351	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HIF1A—esophageal cancer	2.78e-05	0.000344	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CYP19A1—esophageal cancer	2.78e-05	0.000343	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SST—esophageal cancer	2.78e-05	0.000343	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—KDR—esophageal cancer	2.74e-05	0.000338	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TGFBR2—esophageal cancer	2.74e-05	0.000338	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—EP300—esophageal cancer	2.73e-05	0.000338	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—KDR—esophageal cancer	2.72e-05	0.000336	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NOTCH3—esophageal cancer	2.7e-05	0.000334	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GHRL—esophageal cancer	2.7e-05	0.000334	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ALDH2—esophageal cancer	2.7e-05	0.000333	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ADH7—esophageal cancer	2.69e-05	0.000332	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PLCE1—esophageal cancer	2.69e-05	0.000332	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—KDR—esophageal cancer	2.66e-05	0.000329	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FBXW7—esophageal cancer	2.66e-05	0.000328	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HIF1A—esophageal cancer	2.61e-05	0.000323	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SMAD4—esophageal cancer	2.59e-05	0.00032	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NOTCH1—esophageal cancer	2.58e-05	0.000319	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTT1—esophageal cancer	2.57e-05	0.000317	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NOTCH1—esophageal cancer	2.56e-05	0.000316	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—HMOX1—esophageal cancer	2.54e-05	0.000313	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP2A6—esophageal cancer	2.54e-05	0.000313	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NOTCH1—esophageal cancer	2.51e-05	0.00031	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—KDR—esophageal cancer	2.5e-05	0.000309	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ABCB1—esophageal cancer	2.44e-05	0.000301	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NOTCH2—esophageal cancer	2.43e-05	0.000299	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ENO1—esophageal cancer	2.41e-05	0.000297	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTGS1—esophageal cancer	2.41e-05	0.000297	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.4e-05	0.000297	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PSME1—esophageal cancer	2.37e-05	0.000293	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PSME2—esophageal cancer	2.37e-05	0.000293	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ADH1B—esophageal cancer	2.36e-05	0.000291	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NOTCH1—esophageal cancer	2.36e-05	0.000291	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CREBBP—esophageal cancer	2.34e-05	0.000289	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CREBBP—esophageal cancer	2.32e-05	0.000287	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—EGFR—esophageal cancer	2.3e-05	0.000284	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—EGFR—esophageal cancer	2.28e-05	0.000282	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CREBBP—esophageal cancer	2.27e-05	0.000281	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TYMP—esophageal cancer	2.26e-05	0.000278	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—EGFR—esophageal cancer	2.23e-05	0.000276	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—PIK3CA—esophageal cancer	2.2e-05	0.000271	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP26A1—esophageal cancer	2.19e-05	0.000271	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—PIK3CA—esophageal cancer	2.18e-05	0.000269	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TGFBR2—esophageal cancer	2.15e-05	0.000266	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALOX15—esophageal cancer	2.14e-05	0.000264	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CREBBP—esophageal cancer	2.14e-05	0.000264	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—PIK3CA—esophageal cancer	2.14e-05	0.000264	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HIF1A—esophageal cancer	2.12e-05	0.000262	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—EGFR—esophageal cancer	2.1e-05	0.000259	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NOS3—esophageal cancer	2.1e-05	0.000259	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NOS3—esophageal cancer	2.08e-05	0.000257	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP1B1—esophageal cancer	2.05e-05	0.000252	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTO1—esophageal cancer	2.04e-05	0.000252	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TPI1—esophageal cancer	2.04e-05	0.000252	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SMAD4—esophageal cancer	2.04e-05	0.000251	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NOS3—esophageal cancer	2.04e-05	0.000251	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—KDR—esophageal cancer	2.03e-05	0.00025	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—PIK3CA—esophageal cancer	2.02e-05	0.00025	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—PIK3CA—esophageal cancer	2.01e-05	0.000248	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—PIK3CA—esophageal cancer	2e-05	0.000246	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—PIK3CA—esophageal cancer	1.98e-05	0.000244	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—ERBB2—esophageal cancer	1.96e-05	0.000242	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—TP53—esophageal cancer	1.96e-05	0.000242	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.96e-05	0.000241	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—ERBB2—esophageal cancer	1.94e-05	0.00024	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—PIK3CA—esophageal cancer	1.94e-05	0.000239	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP19A1—esophageal cancer	1.92e-05	0.000237	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NOS3—esophageal cancer	1.91e-05	0.000236	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NOTCH1—esophageal cancer	1.91e-05	0.000236	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—ERBB2—esophageal cancer	1.9e-05	0.000235	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.88e-05	0.000232	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CRABP1—esophageal cancer	1.87e-05	0.00023	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—PIK3CA—esophageal cancer	1.82e-05	0.000225	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ERBB2—esophageal cancer	1.79e-05	0.000221	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GNG7—esophageal cancer	1.77e-05	0.000219	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—HMOX1—esophageal cancer	1.76e-05	0.000217	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CREBBP—esophageal cancer	1.73e-05	0.000214	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCND1—esophageal cancer	1.73e-05	0.000214	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCND1—esophageal cancer	1.72e-05	0.000212	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—EGFR—esophageal cancer	1.7e-05	0.00021	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCND1—esophageal cancer	1.68e-05	0.000208	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CDKN1A—esophageal cancer	1.67e-05	0.000207	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HIF1A—esophageal cancer	1.67e-05	0.000206	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.66e-05	0.000205	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CDKN1A—esophageal cancer	1.66e-05	0.000205	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CREBBP—esophageal cancer	1.63e-05	0.000201	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CDKN1A—esophageal cancer	1.63e-05	0.000201	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.63e-05	0.000201	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KDR—esophageal cancer	1.59e-05	0.000197	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—EP300—esophageal cancer	1.59e-05	0.000197	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.58e-05	0.000195	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—EP300—esophageal cancer	1.58e-05	0.000195	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCND1—esophageal cancer	1.58e-05	0.000195	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.56e-05	0.000193	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NOS3—esophageal cancer	1.55e-05	0.000191	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EP300—esophageal cancer	1.55e-05	0.000191	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CDKN1A—esophageal cancer	1.53e-05	0.000189	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NOTCH1—esophageal cancer	1.5e-05	0.000185	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.48e-05	0.000183	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ENO1—esophageal cancer	1.48e-05	0.000183	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	1.48e-05	0.000182	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PSME1—esophageal cancer	1.46e-05	0.00018	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PSME2—esophageal cancer	1.46e-05	0.00018	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—NOS3—esophageal cancer	1.46e-05	0.00018	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EP300—esophageal cancer	1.45e-05	0.00018	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	1.45e-05	0.000179	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MYC—esophageal cancer	1.39e-05	0.000171	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MYC—esophageal cancer	1.38e-05	0.00017	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CREBBP—esophageal cancer	1.36e-05	0.000168	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—EGFR—esophageal cancer	1.36e-05	0.000168	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MYC—esophageal cancer	1.35e-05	0.000167	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—EGFR—esophageal cancer	1.35e-05	0.000166	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—EGFR—esophageal cancer	1.34e-05	0.000165	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTGS2—esophageal cancer	1.33e-05	0.000165	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EGFR—esophageal cancer	1.32e-05	0.000163	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCND1—esophageal cancer	1.28e-05	0.000158	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.28e-05	0.000158	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MYC—esophageal cancer	1.27e-05	0.000156	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.26e-05	0.000156	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EGFR—esophageal cancer	1.24e-05	0.000153	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	1.24e-05	0.000153	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NOS3—esophageal cancer	1.22e-05	0.00015	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.18e-05	0.000146	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EP300—esophageal cancer	1.18e-05	0.000146	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PIK3CA—esophageal cancer	1.18e-05	0.000146	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PIK3CA—esophageal cancer	1.17e-05	0.000144	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PIK3CA—esophageal cancer	1.16e-05	0.000143	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PIK3CA—esophageal cancer	1.15e-05	0.000141	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TP53—esophageal cancer	1.14e-05	0.000141	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ERBB2—esophageal cancer	1.14e-05	0.000141	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TP53—esophageal cancer	1.13e-05	0.00014	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CREBBP—esophageal cancer	1.13e-05	0.000139	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—EP300—esophageal cancer	1.11e-05	0.000137	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TP53—esophageal cancer	1.11e-05	0.000137	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.08e-05	0.000133	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CA—esophageal cancer	1.08e-05	0.000133	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TP53—esophageal cancer	1.04e-05	0.000128	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.04e-05	0.000128	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MYC—esophageal cancer	1.03e-05	0.000127	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—NOS3—esophageal cancer	1.01e-05	0.000124	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCND1—esophageal cancer	1.01e-05	0.000124	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EGFR—esophageal cancer	1.01e-05	0.000124	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CDKN1A—esophageal cancer	9.74e-06	0.00012	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EP300—esophageal cancer	9.27e-06	0.000114	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTGS2—esophageal cancer	9.22e-06	0.000114	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	8.73e-06	0.000108	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TP53—esophageal cancer	8.44e-06	0.000104	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CA—esophageal cancer	8.2e-06	0.000101	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MYC—esophageal cancer	8.08e-06	9.97e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EGFR—esophageal cancer	7.9e-06	9.75e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—EP300—esophageal cancer	7.67e-06	9.46e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CREBBP—esophageal cancer	6.94e-06	8.56e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CA—esophageal cancer	6.86e-06	8.47e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TP53—esophageal cancer	6.64e-06	8.19e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NOS3—esophageal cancer	6.21e-06	7.67e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTGS2—esophageal cancer	5.68e-06	7.01e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CA—esophageal cancer	5.67e-06	7e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—EP300—esophageal cancer	4.72e-06	5.83e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	3.49e-06	4.31e-05	CbGpPWpGaD
